Truace
Subscribe

Machine Learning & Artificial Intelligence in the Development of Gastro-Retentive Drug Delivery Systems: Current Advances & Future Prospectives

The integration of machine learning (ML) and artificial intelligence (AI) into pharmaceutical sciences is reshaping the development of advanced drug delivery systems. Traditional gastroprotective drug delivery systems (GRDDS) are designed to prolong the residence time of oral dosage forms in the stomach to enhance bioavailability and therapeutic efficacy for drugs with narrow absorption windows. However, conventional formulation development often relies on empirical optimization, which is time-consuming and reso…

By the Truvace desk2 min read1 sourcePeer-reviewedTRV-2026-1710· cite & verify
Machine Learning & Artificial Intelligence in the Development of Gastro-Retentive Drug Delivery Systems: Current Advances & Future Prospectives
Levels of estradiol, estrone, and estrone sulfate following a single 2 mg oral dose of micronized estradiol by Medgirl131. CC BY-SA 4.0 · https://creativecommons.org/licenses/by-sa/4.0

In brief

This review abstract describes how machine learning and AI are being applied to gastro-retentive drug delivery systems, which keep oral dosage forms in the stomach longer so drugs with narrow absorption windows work better. It contrasts these data-driven methods with conventional empirical formulation work, which is slow and resource-intensive.

The significance lies in possible gains in design precision, therapeutic outcomes and development cost, plus personalization based on a patient's gastric motility. These are described as promise rather than measured results, and the authors note unresolved needs for better datasets, model interpretability and regulatory integration.

Main points

  1. Neural networks, support vector machines and Bayesian optimization are cited as showing significant potential in formulation modeling.
  2. The models can analyze multidimensional data linking formulation components, physiological variables and release kinetics.
  3. Personalized therapies that account for patient-specific gastric motility are described as a prospect.
  4. The authors expect AI use to reduce developmental costs and improve therapeutic outcomes.

The gain

AI and ML tools can predict drug release, select polymers and simulate gastric behavior, which may cut trial-and-error work and shorten formulation development for stomach-retentive drugs.

The rundown

Gastro-retentive systems are meant to prolong the stomach residence time of oral dosages to improve bioavailability and efficacy. The abstract says conventional development depends on empirical optimization that consumes time and resources.

The named AI methods are artificial neural networks, support vector machines and Bayesian optimization. According to the abstract they have shown potential in predicting release profiles, choosing polymer systems and simulating gastric behavior, and they can reveal patterns that traditional methods would struggle to identify.

The abstract frames the outcomes as likely or promising, and it calls for continued innovation and interdisciplinary collaboration. It reports no specific quantitative results.

Sources

  1. Peer-reviewedInternational Journal of Innovative Science and Research Technology2026-10-16

The debate